CN100592918C - Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain - Google Patents
Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain Download PDFInfo
- Publication number
- CN100592918C CN100592918C CN200510013663A CN200510013663A CN100592918C CN 100592918 C CN100592918 C CN 100592918C CN 200510013663 A CN200510013663 A CN 200510013663A CN 200510013663 A CN200510013663 A CN 200510013663A CN 100592918 C CN100592918 C CN 100592918C
- Authority
- CN
- China
- Prior art keywords
- parts
- blood supply
- brain
- radix
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 230000036770 blood supply Effects 0.000 title claims description 28
- 235000013399 edible fruits Nutrition 0.000 title abstract 3
- 240000006079 Schisandra chinensis Species 0.000 title abstract 2
- 235000008422 Schisandra chinensis Nutrition 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title description 25
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 claims abstract description 38
- 230000001684 chronic effect Effects 0.000 claims abstract description 31
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 241000208340 Araliaceae Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims 4
- 235000019634 flavors Nutrition 0.000 claims 4
- 208000012886 Vertigo Diseases 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 description 29
- 241000700159 Rattus Species 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 15
- 238000011534 incubation Methods 0.000 description 12
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 10
- 230000002792 vascular Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000006386 memory function Effects 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 230000003727 cerebral blood flow Effects 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 241001484259 Lacuna Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 229960000715 nimodipine Drugs 0.000 description 4
- 206010040560 shock Diseases 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000002585 cerebral angiography Methods 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010008097 Cerebral circulatory failure Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 1
- KUQFEFIFTUHBJE-UHFFFAOYSA-N [Cl].C=1C=CSC=1 Chemical compound [Cl].C=1C=CSC=1 KUQFEFIFTUHBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 201000010861 basilar artery insufficiency Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000009570 retrograde amnesia Diseases 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Abstract
An application of the medicinal composition composed of ginseng, schisandra fruit, ophiopogon root, red sage root and wolfberry fruit in preparing the medicines for treating chronic cerebral ischemiais disclosed.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of application of Fructus Schisandrae Chinensis pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine that contain.
Background technology
The origin of notion
Chronic insufficient cerebral blood supply (Chronic Cerebral Circulation Inefficiency, CCCI) blood supply that refers to the brain integral level reduces the state of (being lower than 40-60ml/100g cerebral tissue/per minute), but not focal cerebrum ischemia.It is the new name of disease of year proposition surplus in the of external preceding 10.The old age or the presenium patient that often have some to tell subjective symptomss such as nose heave, dizziness repeatedly clinically, except ocular fundus arteriosclerosis, both also not have cranium brain CT unusual for the focal sign of impassivity infringement, and these patients often are diagnosed as " cerebral arteriosclerosis ".As everyone knows, there are difference in the notion of cerebral arteriosclerosis and clinical diagnosis standard long-term.The chaos of conception that the so-called cerebral arteriosclerosis name of disease of always using for fear of people causes, Japanese health ministry has entrusted " about the definition and the diagnostic criteria tutorial class of cerebral arteriosclerosis disease " to study, cerebral arteriosclerosis has been made the corrigendum motion, think that previously cerebral arteriosclerosis, broad sense system include pathological notion of all diseases related that cerebral arteriosclerosis such as lacuna infarction causes; Narrow sense then refers to because cerebral arteriosclerosis causes the conscious slight neural mental symptom that is produced under the pathological state of disturbance of cerebral circulation, the focal sign of impassivity system and to stare at imaging examination unusual.The 16th apoplexy association of Japan formally was referred to as it chronic cerebral circulatory failure (Chronic Cerebral Circulation Inefficiency), i.e. CCCI in 1991.
International research shows that the harm of chronic insufficient cerebral blood supply is a lot.Specifically be summarized as follows:
● the atrophy of cortex atrophy----cortex is the basic pathological change that causes senile dementia
● the neurogenous degeneration of Hippocampus
● frontal lobe, Hippocampus M type cholinoceptor combination rate decline alba are loosened--and-Yi causes occurring hypomnesis, retrograde amnesia occurs
● glial cells hyperplasia---cause brain function to descend
● capillary bed changes
● other neural subjective symptoms obstacle
The diagnosis of CCCI
For CCCI is studied all sidedly, Japan scholar horizontal well is divided into 3 groups with the age the old man more than 60 years old, the A group is: subjective symptoms outbreaks such as dizziness, carebaria are arranged, more than the ocular fundus arteriosclerosis KWII, but do not have also Non Apparent Abnormality person of any focal neurosigns, CT scan; The B group is: except that subjective symptomss such as no dizziness, other conditions are identical with the A group: the C group is cotemporary healthy old men. and these three groups are all carried out CT, MRI, TCD and PET and check. and check result is: (1) TCD measures common carotid artery blood flow and shows that the .A group all significantly lowers for two groups than B, C; (2) PET shows Interhemispheric blood flow, and the A group significantly lowers than the C group; (3) MRI finds to have in the A group 55%, has 15% old man to find to have cerebral infarction or lacuna infarction in B and the C group.Its conclusion is: cerebral blood flow lowers near normal 80%, subjective symptomss such as dizziness just may occur; The appearance of mental symptom and nervous symptoms then must be lower than below 80% by blood flow.It should be noted that. the patients' of these dizzy outbreaks TCD and PET to be checked find. the blood flow in carotid artery system and cerebral hemisphere perfusion district thereof and the blood flow of vertebra basilar artery lower equally, therefore clinically dizzy symptom is belonged to vertebro-basilar artery insufficiency without exception seem comprehensive inadequately.Japanese health ministry blood circulation diseases tutorial class (1990) is studied the diagnostic criteria of having worked out CCCI in view of the above, sees the following form 1.
Table 1 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (one)
Since subjective symptoms undulatory property growth and decline such as that the circulatory disturbance of brain causes is nose heave, dizziness, but diagnostic imaging aspects such as clinical manifestation and CT all find no the finding of pointing out the vascular encephalosis, and do not belong to TIA category person.
1. clinical manifestation
(1) because various subjective symptomss (carebaria, dizziness etc.) the undulatory property growth and decline that the circulatory disturbance of brain causes.
(2) the focal sign of brain does not appear.
(3) most accompanied with hypertension.
(4) the optical fundus tremulous pulse is arteriosclerosis and sexually revises.
(5) can hear vascular murmur at the perfusion tremulous pulse.
2.CT finding " does not see that the vascular encephalosis becomes ".
Other
(1) cerebral angiography or cervical region TCD etc. show brain perfusion arterial occlusion or narrow change.
(2) cerebral circulation is measured and is shown that blood flow lowers.
(3) age is basically more than 60.
(4) got rid of other disease that can cause above-mentioned subjective symptoms definitely.
(1996) such as nearly rattans make further research 60 routine CCCI patients with said method, except that obtaining above-mentioned similar result of study, still observing CCCI patient further descends with the age growth common carotid artery blood flow, the all sites cerebral blood flow of each cerebral lobe and brain oxidative metabolism rate all descend obviously, think because atherosclerosis risk factors such as hypertension have caused the sclerosis of the mobile arteries and veins of brains.Cause diffuse cerebral blood flow and brain poor metabolism to produce the subjective symptoms of CCCI.Performance is not focal in view of the CCCI cerebral lesion, thus do not occupy transient ischemic attack (transient ischemic attack) category, and drawn more practical CCCI diagnostic criteria (seeing the following form 2).
Table 2 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (two)
1. subjective symptomss such as nose heave, dizzy, different fiber crops are arranged
2. the finding of supporting cerebral arteriosclerosis is arranged.
(1) with hypertension, ocular fundus arteriosclerosis change etc.
(2) vascular murmur of audible and brain perfusion tremulous pulse sometimes.
3. do not see the focal neurosigns of brain.
4. type CT or MRI check that affirmation does not have the cerebral lesion of the device matter of vascular.
5. get rid of because the above-mentioned subjective symptoms that other disease causes.
6. the age is in principle greater than 60 years old.
7. the cerebral circulation inspection confirms that cerebral blood flow is low.
8. definite brain perfusion tremulous pulse such as cerebral angiography, cervical region TCD has obturation, narrow sick.
Be born in 2000 the up-to-date diagnostic criteria of CCCI, its particular content is as follows:
" CCCI diagnostic criteria " version in 2000
1. subjective symptomss such as dizziness, headache, head sink;
2. the finding of supporting cerebral arteriosclerosis is arranged: (1) is with hypertension, ocular fundus arteriosclerosis change etc.; Or the vascular murmur of (2) audible and brain perfusion sometimes tremulous pulse;
3. the focal neurosigns that does not have brain;
4.CT having the organic brain of vascular, MRI do not change;
5. get rid of the above-mentioned subjective symptoms that other diseases causes;
6. the age is in principle greater than 60 years old (can be loosened to more than 45 years old);
7. cerebral circulation confirms that cerebral blood flow is low;
8.DSA or TCD prompting brain perfusion tremulous pulse has inaccessible or narrow change.
Compare with early stage version diagnostic criterias in 96 years, this edition standard is opinion, clear and definite more.Its typing sees the following form 3.
The international typing of table 3 chronic insufficient cerebral blood supply
I type: simple chronic insufficient cerebral blood supply
II type: the change of CCCI+ brain essence (MRI CT find the lacuna infarction)
Over past ten years, domestic many scholars compare comprehensive clinical research to CCCI, the blood properties such as blood viscosity fluid rheology index of observing most of CCCI patients reaches Fibrinogen unusually and obviously raises, and thinks that these also have bigger influence to the formation of CCCI or the fluctuation of symptom unusually; CT sees at the end unusual many patients. cranium brain MRI often can detect ischemic focus (the T1 weighted signal is no abnormal, T2 weighting and proton become to protect the slightly high signal of visible stigma point-like); Adopt the TCD dynamic measurement except that common carotid artery, main vascular flow lowers in the brain of still visible many places, for the clinical diagnosis of CCCI has increased new content.
The treatment of CCCI
According to table 1 and table 3, all dizzinesses that the undulatory property growth and decline are arranged, subjective symptoms such as nose heave, CT, MRI do not see vascular brain organic focus person, should belong to simple property CCCI, be considered to the cerebral infarction state of generation last stage, be necessary to carry out positive control, need improve the risk factor (as hypertension, diabetes, hyperlipemia, obesity etc.) of cerebral circulation and removal ischemic cerebrovascular (ICW), preferably adjoin anti-platelet aggregation medicines such as pyridine with aspirin, thiophene chlorine simultaneously, several days clinical subjective symptomss.And TCD or PET measure brain trunk tremulous pulse are arranged (vertebral-basilar artery system or/carotid artery system) blood flow reduction person, belong to compensatory phase CCCI, should take corresponding prevention and health care measure at the ICVD risk factor that exists, symptoms such as clinical appearance dizziness, CT shows ischemic brain material change (cerebral infarction, lacuna infarction), and TCD or PET confirm to have cerebral blood flow attenuating person.Then belong to CCCIII type or III type, should press lacuna infarction or cerebral infarction respectively and handle.
At present, the medicine for the treatment of the CCCI use clinically has: THA: cholinesterase inhibitor, GST-21: maincenter type N cholinoceptor inhibitor, FK506: immunosuppressant, Nimsuperzine:Cox-2 inhibitor etc., all obtained recent preferably clinical efficacy, late result remains further to be studied.Traditional Chinese medicine of China is having unique effect aspect the treatment CCCI.
Through discovering for many years, has therapeutical effect for chronic insufficient cerebral blood supply and a series of brain diseasess of especially causing by the pharmaceutical composition of forming Radix Ginseng, Fructus Schisandrae Chinensis and Radix Ophiopogonis etc.
Summary of the invention
The object of the invention is to provide the new purposes of aforementioned pharmaceutical compositions aspect the treatment chronic insufficient cerebral blood supply.
The prescription of this pharmaceutical composition is formed as follows by weight ratio:
2～4 parts of Radix Ginsengs, 1～3 part of Fructus Schisandrae Chinensis, 2～4 parts of Radix Ophiopogonis, 2～4 parts of Radix Salviae Miltiorrhizaes, 1～3 part of Fructus Lycii.
Best proportioning is:
3 parts of Radix Ginsengs, 2 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Ophiopogonis, 3 parts of Radix Salviae Miltiorrhizaes, 2 parts of Fructus Lycii.
This patent drug compositions is implemented by following scheme:
The material of getting it filled according to the above ratio, extracting in water 3 times, each 1 hour, merge extractive liquid,, suitably concentrate, add the ethanol of 2 times of amounts, leave standstill 24 hours precipitations, get supernatant concentration and become extractum, relative density is 1.3～1.4, and paste-forming rate is 10%, and qinghuo reagent is spray dried to powder.Wherein, preparation part can also be made any dosage form on other pharmaceuticss according to the process of routine.
Chronic insufficient cerebral blood supply (CCCI) has close getting in touch with brain symptoms such as dizziness, headaches, but at aspects such as pathogenesis and Therapeutic Method tangible difference is arranged again.At present, for chronic insufficient cerebral blood supply, also mainly be based on the pharmaceutical intervention treatment, there is not clear and definite medicine.The medicine of treatment headache not necessarily has the effect of treatment chronic insufficient cerebral blood supply, even also can cause other untoward reaction.
In order to understand the present invention better, tablet (calling in the following text: " tablet ") treatment chronic insufficient cerebral blood supply rat model below by the observation aforementioned pharmaceutical compositions is dizzy, the influence of learning and memory, and the therapeutical effect of this pharmaceutical composition aspect the treatment chronic insufficient cerebral blood supply is described.
Experimental example: tablet in treatment chronic insufficient cerebral blood supply experimentation of the present invention
One, materials and methods
1. animal grouping: 100 of male SD rats, in 10 ages in week, body weight 250 ± 20g is divided into 3 groups at random: tablet group, nimodipine group, model control group, every group each 20.Tablet group 8 weeks after modeling begin to gavage Chinese medicinal tablet 2g/kg/ days, once a day, and continuous 4 weeks; The nimodipine group substitutes tablet with equal-volume nimodipine (500ug/kg), and is surplus with the tablet group; Model control group substitutes tablet with the equal-volume normal saline, and is surplus with the tablet group.
Medicine: nimodipine, nimodipine tablet, Shanxi Yabao Pharmaceutical Co., Ltd. produces, and lot number is that the accurate word (196) of medicine is defended No. 048095 in the Shanxi, every day 3 times, each 20mg, oral; Tablet, Tianjin Tasly Pharmaceutical Co., Ltd.
2. rat chronic cerebral blood supply insufficiency model development: with reference to Torre[Torre Jc, Fortin t, park GA, et al.ChroniccereBRovascular insufficiency induces dementia-induces dementia-like deficits in agedrats.Brain Res, 1992,582 (2): 186-195.] etc. method is made rat both sides ligation of carotid models (2VO).Rat is got the cervical region median incision and cuts off skin through being fixed in behind the 10% chloral hydrate 3.0ml/kg intraperitoneal injection of anesthesia on the operation plate, and passivity is separated each layer tissue, see in the neck that the external carotid artery bifurcated separates vagus nerve, prick bilateral common carotid arteries, layer-by-layer suture with the 4-0 toe-in.Keep 37 ℃-38 ℃ of anus temperature, 23 ℃ of postoperative feeding environment temperature, free diet in the art.
3. learning and memory is measured: adopt Y type maze experiment.Rat is placed in the Y type labyrinth box, began experiment after conforming 3 minutes.The rat of shocking by electricity successively clockwise, the learning and memory in rats achievement has 9 correct required number of shocks to represent to reach in continuous 10 times, how much represent the quality of learning and memory function with reaching 9/10 correct required number of shocks.Laboratory animal respectively at 2VO before, respectively carry out Y type labyrinth test and record achievement behind the 2VO behind 8 weeks, the 2VO behind 12 weeks, the 2VO 16 weeks.
4. measure dizzy incubation period: regulate rotation inducing instrument rotary speed 200r/min.The rat rotation was placed in charged insulating 50 * 50 * 40 experimental boxs on every side in bottom in 1 minute, at once electric shock.(cylindrical rubber of the high 10cm of a diameter 6.5cm is put by experimental box central authorities).Rat stops to jumping onto rubber column escape electric shock and keeping being dizzy incubation period in 30 seconds at rubber column from rotation.Incubation period, long prompt was dizzy serious more more.Each measured once dizzy incubation period to all animals 16 weeks behind 12 weeks, the 2VO behind 8 weeks, the 2VO before 2VO, behind the 2VO.
Two, experimental result
1. tablet is to the influence of chronic insufficient cerebral blood supply learning and memory function: Y shape maze test learning and memory in rats achievement has 9 correct required number of shocks to represent to reach before all rat modelings in continuous 10 times, how much represents the quality of learning and memory function with reaching 9/10 correct required number of shocks.As shown in table 1, correct learning and memory function approximately needs about 18-20 time before the rat 2VO.Behind the rat 2VO, along with time lengthening, the learning and memory achievement descends gradually.The correct learning and memory achievement of 2VO12 week rat is electric shock about 39.5 times, and 16 weeks were about 58.3 times; Nimodipine group and 2VO group no significant difference, P＞0.05.12 weeks of tablet group, the correct learning and memory achievement with 16 weeks was that shock count is respectively 29.2 and 43.2 times, and organizing with 2VO relatively has notable difference, P＜0.05.The prompting tablet can effectively improve the 2VO learning and memory function.
Table 1 tablet is to the influence of chronic insufficient cerebral blood supply learning and memory function
* compare P＜0.05 with the 2VO group
2. the tablet influence dizzy to the chronic insufficient cerebral blood supply rat: as shown in table 2, be about 96 seconds dizzy incubation period before all rat modelings.Behind the rat 2VO, along with time lengthening increases dizzy incubation period.As shown in table 1, be respectively 17.3 ± 2.3,39.5 ± 4.3,58.3 ± 8.5 the dizzy incubation period that 2VO organizes 8 weeks, 12 weeks, 16 weeks, and notable difference arranged, P＞0.05 before the 2VO.Nimodipine treatment each time point of back and 2VO group no significant difference, P＞0.05.Be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in tablet group 12 week and 16 weeks, notable difference, P＜0.05 relatively arranged with the 2VO group.The prompting tablet can effectively improve dizzy effect incubation period of 2VO rat.
Table 2 tablet is to the dizzy preclinical influence of chronic insufficient cerebral blood supply rat
# and sham operated rats be P＜0.05 relatively; * compare P＜0.05 with the 2VO group
Three, discuss
1992, Torre etc. reported that at first ligation rat bilateral carotid causes the chronic insufficient cerebral blood supply model to succeed.Subsequently studies confirm that 2VO rat hippocampus CA1 district neural degeneration, cortex atrophy, white matter are loose, microglia hypertrophy and capillary bed change etc.The 2VO rat promptly enters chronic phase after 3 weeks, and frontal lobe appears to the 2VO3 rat in rat after 3 months, Hippocampus M type cholinoceptor combination rate descends, and monoamine class mediator changes and the energy metabolism compensatory activates and neuroethology changes.
This experimentation confirms that aspect learning and memory mensuration the correct learning and memory achievement in 12 weeks of tablet group and 16 weeks is that shock count is respectively 29.2 and 43.2 times, with the 2VO group notable difference, P＜0.05 is arranged relatively.The prompting tablet can effectively improve the 2VO learning and memory function; In dizzy incubation period of influence experiment, be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in 12 weeks of tablet group and 16 weeks, with the 2VO group notable difference, P＜0.05 are arranged relatively.The prompting tablet can effectively improve dizzy effect incubation period of 2VO rat.
In sum, this experimental result shows that this pharmaceutical composition has the chronic insufficient cerebral blood supply of improvement rat blood circulation, improves effects such as the dizziness that causes because of chronic cerebral ischemia and dysmnesia.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Embodiment 1
According to the following weight material of getting it filled: Rhizoma Chuanxiong 40g, Radix Salviae Miltiorrhizae 30g, Radix Curcumae 20g, Rhizoma Typhonii 30g, Calculus Bovis 15g, Rhizoma Gastrodiae 20g, Flos Chrysanthemi 30g, Radix Paeoniae Alba 10g, Herba Asari 30g, Radix Angelicae Dahuricae 10g, Borneolum Syntheticum 10g;
The material of getting it filled according to the above ratio, extracting in water 3 times, each 1 hour, merge extractive liquid,, suitably concentrate, add the ethanol of 2 times of amounts, leave standstill 24 hours precipitations, get supernatant concentration and become extractum, relative density is 1.3～1.4, and paste-forming rate is 10%, and qinghuo reagent is spray dried to powder.
It is standby that above-mentioned powder, lactose, pregelatinized Starch, cross-linking sodium carboxymethyl cellulose are crossed 65 mesh sieves respectively, by equivalent progressively increase method and other adjuvant mix homogeneously, mistake 65 mesh sieves 3 times; Survey angle of repose, less than 30 °; Survey content, decide content; Tabletting.
Claims (4)
1. the application of pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine, wherein the weight proportion of each flavour of a drug of said composition is as follows:
2～4 parts of Radix Ginsengs, 1～3 part of Fructus Schisandrae Chinensis, 2～4 parts of Radix Ophiopogonis, 2～4 parts of Radix Salviae Miltiorrhizaes, 1～3 part of Fructus Lycii.
2. application according to claim 1, wherein the weight proportion of each flavour of a drug is as follows:
3 parts of Radix Ginsengs, 2 parts of Fructus Schisandrae Chinensis, 3 parts of Radix Ophiopogonis, 3 parts of Radix Salviae Miltiorrhizaes, 2 parts of Fructus Lycii.
3. the application of pharmaceutical composition in the hypomnesis medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug of compositions is as follows:
2～4 parts of Radix Ginsengs, 1～3 part of Fructus Schisandrae Chinensis, 2～4 parts of Radix Ophiopogonis, 2～4 parts of Radix Salviae Miltiorrhizaes, 1～3 part of Fructus Lycii.
4. the application of pharmaceutical composition in the vertigo medicament that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug of compositions is as follows:
2～4 parts of Radix Ginsengs, 1～3 part of Fructus Schisandrae Chinensis, 2～4 parts of Radix Ophiopogonis, 2～4 parts of Radix Salviae Miltiorrhizaes, 1～3 part of Fructus Lycii.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510013663A CN100592918C (en) | 2005-06-03 | 2005-06-03 | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510013663A CN100592918C (en) | 2005-06-03 | 2005-06-03 | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872277A CN1872277A (en) | 2006-12-06 |
| CN100592918C true CN100592918C (en) | 2010-03-03 |
Family
ID=37482985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510013663A Expired - Fee Related CN100592918C (en) | 2005-06-03 | 2005-06-03 | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100592918C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014245A1 (en) * | 2008-07-30 | 2010-02-04 | Nestec S.A. | Methods and compositions for preventing, reducing, or treating damage caused by ischemia and ischemia-like conditions |
| CN102860496B (en) * | 2012-10-09 | 2015-06-03 | 三普药业有限公司 | Oxidation-resisting health-care food for improving immunity and preparation method thereof |
| CN105497495A (en) * | 2015-12-21 | 2016-04-20 | 北京同仁堂科技发展股份有限公司 | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof |
| CN105535425B (en) * | 2015-12-21 | 2019-05-31 | 北京同仁堂科技发展股份有限公司 | A kind of Chinese medicine composition with strengthen immunity effect and preparation method thereof and purposes |
| CN105497496B (en) * | 2015-12-21 | 2019-01-15 | 北京同仁堂科技发展股份有限公司 | It is a kind of with Chinese medicine composition and preparation method thereof and purposes for improving male's sexual effect |
-
2005
- 2005-06-03 CN CN200510013663A patent/CN100592918C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872277A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872329A (en) | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100592918C (en) | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872214B (en) | Application of medication composition of containing notoperygium root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872287A (en) | Application of medication composition of containing gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872187B (en) | Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872276B (en) | Application of medication composition of containing extractive of astragalus root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100548362C (en) | A kind of Rhizoma Typhonii pharmaceutical composition that contains is preparing the application for the treatment of in the chronic insufficient cerebral blood supply medicine | |
| CN100411652C (en) | Use of medicinal composition in preparing medicine for treating chronic brain blood supply deficiency | |
| CN1872081B (en) | Application of kudzuvine root flavone in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN100563699C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Rhizoma Ligustici | |
| CN1872213B (en) | Application of medication composition of containing peach kernel in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872297B (en) | Application of medication composition of Guangdong date in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN100563692C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Magnetitum | |
| CN1872170B (en) | Application of medication composition of containing corydalis tuber in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN100455316C (en) | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency | |
| CN1872319B (en) | Application of medication composition of containing polygala root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872291A (en) | Application of medication composition of containing uncaria in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100592911C (en) | Application of medication composition containing BV6 in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872286B (en) | Application of medication composition of containing notoginseng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872178B (en) | Application of medication composition of containing white peony root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN100563702C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Fructus Gardeniae | |
| CN1872288A (en) | Application of medication composition of containing eucommia in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872154B (en) | Application of medication composition of containing Yunnan red sage root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN100450539C (en) | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency | |
| CN1872068B (en) | Application of medication composition of containing acetamino phenol in treating insufficiency of blood supply for brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100303 Termination date: 20190603 |